FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ANDO GORAN						2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC									elationship ck all appl Direct	,		erson(s) to Is		
					ENZ	ENZN]								Office	Officer (give title		Other (specify		
(Last)	(Fi	rst) (saction (Mo	ction (Month/Day/Year)					below			below)	·							
C/O ENZON PHARMACEUTICALS, INC.							11/11/2004													
685 ROUTE 202/206						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					pplicable	
(Street)													X Form filed by One Reporting Person				on			
BRIDGEWATER NJ 08807															Form filed by More than One Reporting Person					
(City)	(St	tate) (Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)						Execution					rities Acc ed Of (D)			5. Amo Securit Benefic Owned	ies cially	Fori (D) (m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership		
										v	Amoun	nt (A) or (D)		rice	Report Transa	Following Reported Fransaction(s) Instr. 3 and 4)		tr. 4)	(Instr. 4)	
Common Stock ⁽¹⁾ 11/11/20						004			A		1,566 ⁽²⁾ A		A	\$0	0 1,566			D		
		T	able II						uired, Dis						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transact Code (In 8)		ion of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amo or Num of Shar	ber						
Common Stock (Right to Buy) ⁽³⁾	\$15.96	11/11/2004			A		20,000		(4)	11.	/11/2014	Common Stock	20,0	000	\$0	20,000		D		

Explanation of Responses:

- 1. Restricted stock granted by Enzon Pharmaceuticals, Inc. ("Enzon") pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).
- 2. Of the 1,566 shares granted, 522 will vest on November 11, 2005, 522 will vest on November 11, 2006 and the remaining 522 will vest on November 11, 2007 so long as Dr. Ando is a member of the
- 3. Stock option granted by Enzon pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).
- 4. Of the 20,000 options granted, 6,667 will vest on November 11, 2005, 6,667 will vest on November 11, 2006 and the remaining 6,666 will vest on November 11, 2007 so long as Dr. Ando is a member of the board on the above dates.

/s/ Gary A. Smith (Attorney-in- 11/15/2004 Fact)

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.